A New Horizon in Fibrosis Treatment: The First PDE4B-Selective Therapy Emerges
A recent review in Trends in Pharmacological Sciences highlights the development of Nerandomilast as the first phosphodiesterase 4B (PDE4B)-selective therapy for idiopathic pulmonary fibrosis (IPF). This represents a significant shift from non-selective PDE4 inhibitors, which have been limited by side effects. The article discusses the drug’s mechanism, which targets a specific inflammatory pathway central to fibrotic progression, and its potential clinical implications for a disease with high unmet need. This targeted approach in pulmonary fibrosis offers a new paradigm that may have broader relevance for treating organ fibrosis, including liver fibrosis and cirrhosis.
Study Significance: For hepatology professionals, the advent of a tissue-specific, targeted anti-fibrotic like Nerandomilast provides a crucial proof of concept. It underscores the therapeutic potential of moving beyond broad-spectrum anti-inflammatories to precision agents that modulate key fibrotic pathways with fewer off-target effects. This development directly informs the ongoing search for novel pharmacotherapies in metabolic liver disease, NASH, and other chronic liver conditions where fibrosis drives morbidity, suggesting that lessons from pulmonary fibrosis could accelerate drug discovery in hepatology.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
